iCAD is a medical technology company providing cancer detection and therapy solutions. Co. has two segments: Cancer Detection and Cancer Therapy. In the Cancer Detection segment, Co.'s solutions include image analysis and workflow solutions that enable healthcare personnel to serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of Artificial Intelligence and Computer-Aided Detection systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Cancer Therapy segment, Co. provides the Xoft Axxent Electronic Brachytherapy System, an isotope-free cancer treatment platform technology. The ICAD YTD return is shown above.
The YTD Return on the ICAD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ICAD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ICAD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|